share_log

公告精选 | 福耀玻璃2023年净利润56.29亿元,同比增18.37%;三大航2月客座率均恢复至八成以上

Selected announcements | Fuyao Glass's net profit in 2023 was 5.629 billion yuan, up 18.37% year on year; passenger occupancy rates of the three major airlines all recovered to more than 80% in February

Futu News ·  Mar 18 08:04

A selection of major announcements

1. Fuyao Glass announced annual results: net profit increased 18.37% to 5.629 billion yuan

$FUYAO GLASS (03606.HK)$According to the announcement of annual results, in 2023, the company achieved consolidated revenue of RMB 33.161 billion, an increase of 18.02% over the same period of the previous year; realized profit before tax of RMB 6.715 billion, an increase of 20.38% over the same period of the previous year; realized annual profit attributable to the company owners of RMB 5.629 billion, an increase of 18.37% over the same period of the previous year; and achieved earnings per share of RMB 2.16 yuan, an increase of 18.68% over the same period of the previous year. It is proposed to distribute a cash dividend of RMB 1.30 (tax included) per share.

2. Meitu: Adjusted net profit of about 370 million yuan in 2023, an increase of 233.2% over the previous year

$MEITU (01357.HK)$In 2023, adjusted net profit attributable to equity holders of the parent company reached approximately RMB 370 million, an increase of 233.2% over the previous year. Revenue increased by approximately 29.3% year over year to approximately RMB 2.7 billion. As of December 31, 2023, the number of monthly active users reached about 250 million, a year-on-year increase of 2.6%.

3. The passenger occupancy rate of the three major airlines all recovered to over 80% in February

$AIR CHINA (00753.HK)$: In February, passenger capacity investment increased 51.4% year on year, passenger turnover increased 70.0% year on year, passenger occupancy rate was 82.5%, up 9.0 percentage points year on year;$CHINA SOUTH AIR (01055.HK)$: In February, passenger capacity investment increased 39.13% year on year, passenger turnover increased 55.49% year on year, passenger occupancy rate was 85.60%, up 9.00 percentage points year on year;$CHINA EAST AIR (00670.HK)$: In February, passenger capacity investment increased 57.81% year on year; passenger turnover increased 80.30% year on year, and passenger occupancy rate was 83.38%, up 10.40 percentage points year on year.

4. The total contract sales amount of Longhu Group in February was 5.75 billion yuan

3/15,$LONGFOR GROUP (00960.HK)$Release of unaudited operating data and additional land reserves for February 2024. By the end of February 2024, the Group had achieved a total contract sales amount of RMB 12.76 billion, a contract sales area of 906,000 square meters, a total contract sales amount of RMB 5.75 billion and a contract sales area of RMB 380,000 square meters in February; in February, it realized a contract sales amount of RMB 3.75 billion belonging to the company's shareholders' rights, and a contract sales area of 253,000 square meters belonging to the company's shareholders' rights.

5. Kuaishou-W spent about HK$24.7.783 million to buy back 503,200 shares on March 15

$KUAISHOU-W (01024.HK)$An announcement was issued on March 15, 2024 to repurchase 503,200 shares at a cost of approximately HK$247.783 million, at a repurchase price of HK$48.7-49.75 per share.

Important matters

$DALIPAL HLDG (01921.HK)$Plan to establish a regional headquarters, R&D center, smart factory and data control center in the Middle East

Earnings Report

$GCL TECH (03800.HK)$Revenue from continuing operations in 2023 is approximately RMB 33.7 billion

$TOT BIOPHARM-B (01875.HK)$Announced annual results, revenue increased sharply by 77%, and the Group's hematopoietic capacity continued to increase

$IVD MEDICAL (01931.HK)$Profit attributable to parent company owners of 238 million yuan increased 13.4% year-on-year in 2023

$ZGC TEC LEASING (01601.HK)$Annual profit of about 260 million yuan increased by about 14.9% year-on-year

$SEAZEN (01030.HK)$Yingxi: Expected net profit of 800 million yuan to 1 billion yuan in 2023

$MOBVISTA (01860.HK)$Annual revenue of US$1,054 million increased 17.9% year over year

$PHOENIX TV (02008.HK)$Annual revenue of approximately HK$2,468 billion decreased by 17.8% year-on-year

$YUEYUN TRANS (03399.HK)$Turned a loss into a profit of 202 million yuan in 2023

$KANGQIAO SER (02205.HK)$2023 results released: revenue of approximately $934 million, up 17.8% year over year

$QINQIN FOODS (01583.HK)$The cumulative sales revenue in 2023 was about 980 million yuan, up 2.5% year-on-year

$SHANSHUI CEMENT (00691.HK)$Revenue of about RMB 18.116 billion in 2023 decreased by 15.7% year-on-year

$LUZHU BIOTECH-B (02480.HK)$Annual adjusted loss increased by about 46.6% to approximately $223 million

$XINGFA ALUM (00098.HK)$Yingxi: Annual net profit is expected to be no less than 780 million yuan

$CHINA GLASS (03300.HK)$Profit Warning: Expected loss of no more than 500 million yuan in 2023

$PER ENERGY (02798.HK)$Net profit after tax is expected to be around 470 million yuan to 520 million yuan in 2023

$JIUTAI RCB (06122.HK)$Annual net profit is expected to drop by about 85%

$YUNFENG FIN (00376.HK)$Annual profit of approximately HK$390 million is expected to turn a loss into a profit year over year

$SEA HOLDINGS (00251.HK)$Profit Alert: Expected loss of approximately HK$850 million in 2023

Operational data

$NCI (01336.HK)$Accumulated original insurance premium income of 39.6 billion yuan from January to February

$CHINA COAL (01898.HK)$: Commercial coal sales in February decreased 16.2% year-on-year to 18.28 million tons

Pharmaceutical Innovation

$SIMCERE PHARMA (02096.HK)$: Application for marketing of a new injectable sulvisitamab drug was accepted by the State Drug Administration

$SINO BIOPHARM (01177.HK)$: “Ranilano” (pan-PPAR agonist) and “TQA2225" (recombinant human FGF21-FC fusion protein) are currently undergoing phase III and phase II clinical trials in China, respectively

Acquisition and sale

$SEACON (02409.HK)$Proposed acquisition of an oil tanker for $30.1 million

$LAI SUN DEV (00488.HK)$Proposed sale of Hong Kong properties for HK$80 million

$ELL ENV (01395.HK)$Proposed sale of wood pellet production business

Equity incentives

$ALI HEALTH (00241.HK)$A total of 1.93 million restricted share units were granted

Repurchase cancellation

$AIA (01299.HK)$On March 15, it cost HK$280 million to buy back 4.6 million shares

$STANCHART (02888.HK)$On March 14, it cost £2.59 million to buy back 3.85 million shares

$HSBC HOLDINGS (00005.HK)$On March 14, 1,5284 million shares were purchased at HK$904.21 million

$MOBVISTA (01860.HK)$The Board approved a capital increase of HK$80 million to the current share repurchase scheme

$YUM CHINA (09987.HK)$On March 14, 114,400 shares were purchased at HK$38.272,800

$HAIER SMARTHOME (06690.HK)$On March 15, it spent 28.47 million yuan to buy back 1.193 million A-shares

$KUAISHOU-W (01024.HK)$On March 15, 503,000 shares were repurchased at HK$24.78 million

$ASYMCHEM (06821.HK)$On March 15, it spent 1999 million yuan to buy back 201,000 A-shares

$SWIRE PACIFIC A (00019.HK)$On March 15, 252,000 shares were purchased at HK$16.65,800

edit/lambor

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment